Acute respiratory distress syndrome future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Brian Shaller, M.D. [2]

Overview[edit | edit source]

Several medical therapies, including granulocyte macrophage colony stimulating factor (GM-CSF) are currently under investigation as potential treatments for ARDS.

Investigational therapies[edit | edit source]

Granulocyte macrophage colony stimulating factor (GM-CSF):

• An observational study found an association between higher levels of GM-CSF in brochoalveolar lavage (BAL) fluid and improved survival in patients with ARDS^[1]
• A study of 6 patients with ARDS due to pneumonia who were administered nebulized GM-CSF demonstrated improvements in lung compliance and mortality scores; 4 of 6 patients survived to discharge^[2]

• A randomized clinical trial (RCT) is currently underway to further study the potential efficacy of inhaled GM-CSF in ARDS

Macrolide antibiotics:

• An observational study of 47 patients with acute lung injury (ALI) demonstrated an association between administration of macrolide antibiotics and both early discontinuation of mechanical ventilation as well as improved survival at 180 days^[3]

References[edit | edit source]